Start with the fact that changes how the rest of the report reads: of the three markers on a typical metabolic panel, only HbA1c is endorsed by any guideline body as a diagnostic test. Fasting insulin and HOMA-IR are not, in India or internationally. They are research instruments that have found their way onto consumer lab menus. That does not make them useless, and this guide explains what each one measures, which Indian reference points genuinely exist, and why two labs can hand you two different insulin numbers from the same blood.

• Only HbA1c has a guideline-endorsed diagnostic role. Fasting insulin and HOMA-IR are research instruments, not diagnostic tests.
• HOMA-IR is not a separate blood test. It is a calculated index from fasting glucose and fasting insulin, using a formula.
• Indian HOMA-IR cut-offs in the published literature range from 1.23 to 3.6, derived from different cohorts and methods, none validated against clinical outcomes.
• Insulin immunoassays are not standardised between manufacturers. Results from different labs are not directly comparable.
• HOMA1 and HOMA2 return different values from the same blood sample. Applying a threshold from one to a result from the other will misclassify.

Fasting insulin:

A direct measurement of insulin in blood drawn after an overnight fast. Indian labs report it in µIU/mL (also written µU/mL or mIU/L, which are numerically identical). Some labs report pmol/L instead. The standard conversion is 1 µIU/mL to roughly 6.0 pmol/L. If you are comparing two reports, check the units first.

HOMA-IR:

Not a separate blood test. It is a calculated index from a single paired fasting glucose and fasting insulin sample. The original 1985 formula multiplies fasting insulin (µU/mL) by fasting glucose (mmol/L) and divides by 22.5. A version using glucose in mg/dL divides by 405 instead. Some Indian diagnostic chains bundle the two tests and report the result as a named "HOMA-IR test," which is why it can look like a standalone investigation on a price list.

HbA1c:

Measures the fraction of haemoglobin with glucose irreversibly attached, reflecting average blood glucose over the preceding 8 to 12 weeks, weighted toward the most recent 30 days. Indian labs report it as an NGSP percentage. The conversion is 6.5% NGSP equals 48 mmol/mol IFCC.

All three sit downstream of the same underlying physiology, which is what insulin resistance is and how the pancreas compensates for it. The panel is an attempt to see that process from three angles, with very different degrees of success.

This is the most consequential thing to know before reading a number off the page, and it is rarely said in the room where the test is sold.

Neither the American Diabetes Association nor the European Association for the Study of Diabetes endorses HOMA-IR for routine clinical use. The clinical literature is direct about it: HOMA-IR does not appear in any major diabetes diagnostic guideline, and the recommended use is to estimate the prevalence of insulin resistance across populations when direct measurement by euglycaemic clamp is not feasible, mainly in research settings for large-scale studies. A 2024 study of 5,578 individuals found that adding HOMA-IR to prediction models already using HbA1c and fasting glucose did not materially improve performance.

India's position is the same, expressed by omission:

• RSSDI defines diabetes and prediabetes using fasting plasma glucose, the two-hour oral glucose tolerance test, and HbA1c.
• Fasting insulin and HOMA-IR do not appear among its diagnostic criteria.
• No Indian professional body has published an endorsed clinical HOMA-IR cut-off for diagnosis.

The Indian numbers that do exist, are population-research derivations rather than clinical decision thresholds. That distinction is not a technicality.

That leaves a real gap between what an Indian patient is told a metabolic panel means and what the guideline bodies say those tests are validated for. Fasting insulin and HOMA-IR can still inform a clinician's thinking, particularly where a picture is ambiguous. What they cannot do is diagnose anything on their own, and no result from either should be read as a diagnosis by the person holding the report.

Different labs use different machines, and those machines are not calibrated to the same reference standard. This is the caveat almost never printed on a report.

An ADA workgroup evaluation of 12 commercial insulin methods from nine manufacturers found among-assay variability of 12% to 66%, with a median of 24%. Distributing a common reference preparation to all of them did not fix the discordance. A companion comparison against isotope-dilution mass spectrometry found biases ranging from minus 17% to plus 42% depending on the manufacturer.

The problem has not been solved since. A 2023 comparison of seven current assay kits found relative standard deviations of 1.7% to 23.2% between platforms and concluded that conversion factors and traceability chains are not yet harmonised.

What this means practically:

• A reference range or HOMA-IR cut-off derived on one assay platform does not reliably transfer to a result from a different platform.
• Indian labs do not routinely disclose which platform produced a given number.
• Comparing this year's insulin result to last year's from a different lab is not a valid comparison.
• Comparing your number to one you read somewhere else is also not reliable.

The 1985 formula, now called HOMA1, was refined in 1998 into HOMA2, a non-linear computer model that accounts for variation in hepatic versus peripheral glucose resistance. HOMA2 has no closed-form equation and has to be run through the Oxford Diabetes Trials Unit's calculator.

Getting this wrong makes every threshold meaningless, because the two models return different values from the same blood sample. HOMA2-IR runs systematically lower than HOMA1-IR. A HOMA1 cut-off near 2.7 corresponds to roughly 1.8 on HOMA2. Applying a HOMA1 threshold to a HOMA2 result, or the reverse, will misclassify.

Nearly all published Indian cut-offs use the HOMA1 linear formula. No Indian cohort study reports a validated HOMA2-derived population cut-off at all.

The Oxford unit that developed both models states there is no absolute value for HOMA indices, because results depend on the specific assays used for glucose, insulin and C-peptide. It declines to publish universal thresholds for either model. HOMA2 is considered more accurate but is used mainly in research, not as a routine clinical report output.

Below is every traceable Indian-derived cut-off found in the peer-reviewed literature behind this article, with what it was derived from and whether it has been validated. These are population-research figures that a clinician weighs alongside history and examination. They are not a scale to place your own result on.

CURES-105, normal-glucose-tolerance subgroup, Chennai (2011)

The HOMA-IR cut-off was 2.58. It represented the 75th percentile of the normal-glucose-tolerance subgroup.

Outcome-validated: No. It was a descriptive percentile, not clamp- or outcome-validated.

Indian adolescent cohort (2013)

The HOMA-IR cut-off was 2.5. It was derived using ROC analysis against ATP III and IDF metabolic syndrome criteria, with sensitivity above 70% and specificity above 60%.

Outcome-validated: No. It was based on a cross-sectional ROC against metabolic syndrome only.

South Indian population study (2023)

The proposed HOMA-IR cut-off was 1.23. It was described as a population-specific cut-off, but the available abstract does not fully detail its derivation.

Outcome-validated: No. It was descriptive.

Indian cohort (2025)

The HOMA-IR cut-off was 3.6. It was derived from the 95th percentile, with sensitivity of 78.6% and specificity of 72.9%.

Outcome-validated: No. It was a preprint, not peer-reviewed, and the reference standard was unclear.

A 2024 Indian cross-sectional study puts the position plainly, stating that there is no strong evidence for the cut-off values of HOMA-IR for Indian individuals.

The spread is the finding. Indian primary literature has not converged: 1.23 to 3.6 is not a range, it is four unrelated numbers from four cohorts using three different derivation methods, none prospectively validated against progression to diabetes, cardiovascular events, or the euglycaemic clamp gold standard. The adolescent study behind the 2.5 figure says as much itself, noting that before its own work there was no consensus and no data defining HOMA-IR cut-off values for Indian adolescents.

Where the "1.4 to 2.5 Asian range" comes from:

It does not resolve to a primary source. The research behind this article could not trace the widely repeated claim that Asian or Indian HOMA-IR thresholds sit at 1.4 to 2.5 to any originating Indian publication. What exists is the scatter above. The figure 2.5 recurs because it is a commonly derived ROC cut-off against metabolic syndrome in more than one study, with unrelated studies also landing near 2.0 to 2.5. That is coincidental convergence across different populations and different outcomes, not a validated Asian threshold. Where "1.4" or similarly precise combined ranges attributed to Asians appeared at all, they appeared on diagnostic-chain and lab test-booking pages rather than in any traceable peer-reviewed derivation.

HbA1c is the exception on this panel. It is guideline-endorsed and has Indian validation work behind the threshold India uses.

RSSDI's expert panel recommends HbA1c at or above 6.5% as the diagnostic cut-off for diabetes in Indian patients, based on pooled data from four Indian centres in Chandigarh, Chennai, Bangalore and Andhra Pradesh. A Chandigarh community-based study found that 6.5% gives 88% specificity, while 7.0% gives 92% sensitivity. For prediabetes, RSSDI has adopted the ADA band of 5.7% to 6.4% for the Indian context, while noting a study in high-risk South Indians that proposed an alternative optimal prediabetes cut-off of 5.9%. RSSDI cites that figure but has not adopted it as the primary standard.

The international disagreement on prediabetes thresholds is live and unresolved:

• ADA: Recognises 5.7% to 6.4% HbA1c as one of three valid prediabetes criteria.
• WHO: Does not endorse HbA1c for diagnosing prediabetes at all, and uses a higher fasting glucose threshold (110 to 125 mg/dL vs the ADA's 100 mg/dL).
• RSSDI: Has sided with the ADA approach for Indian patients.

One boundary matters here. That endorsement is for glycaemia, meaning blood glucose exposure over recent weeks. It is not an endorsement of HbA1c as a test for insulin resistance, which is a different question with a different answer, covered in why HbA1c alone misses insulin resistance in Indian bodies.

Pre-analytic conditions change results without anything changing in the person, and they account for a good share of confusing reports.

The most common pre-analytic issues:

• Fasting: Fasting glucose and fasting insulin both require at least eight hours without food or drink other than water. HbA1c requires no fasting at all.
• Sample handling: Insulin samples need centrifugation within about an hour of collection. Delay, improper refrigeration, or haemolysis all distort the measured concentration.
• Acute illness or stress: Recent illness, physiological stress, or steroid exposure can transiently raise both glucose and insulin, unrelated to a person's underlying metabolic state.
• Single results: RSSDI's criteria require any single abnormal result to be repeated on a separate day before it is treated as diagnostic, unless it is unequivocally abnormal or accompanied by classic symptoms.

Three misreadings recur often enough to name:

• Treating a single fasting insulin or HOMA-IR value as a diagnosis: Neither is a diagnostic test by guideline consensus, and even within research use no single value is definitive without repeat testing or corroborating markers.
• Comparing results across labs or across time without knowing the assay platform: Given among-assay variability of 12% to 66%, a change between two reports from different labs may be entirely the assay, not you.
• Reading one marker in isolation: A normal fasting glucose alongside a raised insulin can still reflect compensated insulin resistance, which is precisely the situation the index was designed to detect in populations, not to rule out in an individual.

Fasting insulin and HOMA-IR remain specialist rather than routine tools in India, a point also made in the context of testing in your twenties. Easy to buy is not the same as easy to interpret.

Two of the three numbers on this panel have no guideline-endorsed diagnostic role, no standardised assay behind them, and no Indian cut-off validated against clinical outcomes. The third (HbA1c) has an Indian-validated threshold, but answers a narrower question than most people ordering it assume.

None of that is a reason to dismiss the panel. It is the reason interpretation is a clinical act, not a lookup. The value of these markers is in what they add to a history, an examination, and the full clinical picture. A normal result on any one of them settles less than it appears to, in people whose BMI reads normal but whose risk profile tells a different story.

Holding a metabolic report you cannot interpret on your own? A metabolic assessment with Voy puts the numbers next to your history, medication list, and clinical examination, which is the only context in which any of them mean something specific to you.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.